Upstream Bio Inc Dossier - Source-backed chat

Upstream Bio Inc

UPBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.18

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.27Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $288.6M

Enterprise Value $210.5M

Shares Outstanding 54.6M diluted

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Upstream Bio, Inc. (NASDAQ: UPB) is a clinical-stage biotechnology company uniquely positioned in the high-value respiratory and inflammatory disease market. The company's lead asset, verekitug (UPB-101), is a highly potent monoclonal antibody that targets the thymic stromal lymphopoietin (TSLP) receptor. Unlike existing therapies that target the TSLP ligand, verekitug blocks the receptor directly, achieving complete pathway shutdown. Positive Phase 2 data in severe asthma (VALIANT trial) and chronic rhinosinusitis with nasal polyps (VIBRANT trial) support its potential to deliver best-in-class efficacy with a highly convenient quarterly at-home dosing regimen. Backed by a robust cash position of $294.6 million as of March 31, 2026, which provides a runway through 2027, Upstream Bio represents a compelling investment opportunity as it prepares to transition into Phase 3 development in early 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$33.50

High · most bullish analyst$75.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$8.0020%

End-of-Phase 2 meetings with the FDA result in regulatory delays or requirements for additional preclinical or clinical studies, pushing back the initiation of Phase 3 trials. Competitors launch next-generation formulations or alternative therapies that erode verekitug's convenience advantage. Clinical development costs escalate, shortening the cash runway and forcing a highly dilutive capital raise before key data readouts.

Base CaseCentral scenario

$38.2550%

Phase 3 trials for severe asthma and CRSwNP are successfully initiated in Q1 2027 following constructive End-of-Phase 2 meetings with the FDA in mid-2026. Verekitug's clinical profile remains strong, with no new safety signals. The company's cash runway remains sufficient to fund operations through 2027, allowing it to reach key clinical milestones without immediate dilutive financing.

Bull CaseUpside scenario

$50.0030%

Verekitug demonstrates superior efficacy in Phase 3 trials compared to existing biologics like Tezspire and Dupixent, driven by its unique receptor-targeting mechanism. The quarterly at-home dosing regimen is widely adopted by physicians and patients, capturing significant market share in severe asthma and CRSwNP. Additionally, the Phase 2 VENTURE trial in COPD yields positive results, expanding the addressable market and driving a substantial valuation re-rating.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Mechanism of Action: Verekitug is the only known TSLP receptor antagonist in clinical development, offering complete pathway blockade and superior potency compared to ligand-targeting alternatives.
Compelling Phase 2 Data: Positive top-line results from the VALIANT (severe asthma) and VIBRANT (CRSwNP) trials demonstrate significant improvements in disease measures and support extended quarterly dosing.
Convenient Dosing Profile: The potential for a high-dose quarterly at-home regimen provides a major competitive advantage over existing biologics that require more frequent administration.
Strong Financial Position: A cash reserve of $294.6 million as of Q1 2026 secures the company's operational runway through 2027, covering the planned initiation of Phase 3 trials.

Key Investment Risks

Asset Concentration: Upstream Bio's valuation is heavily dependent on a single clinical asset, verekitug, exposing investors to high binary risk.
Regulatory and Execution Risks: Any delays in FDA End-of-Phase 2 meetings or Phase 3 trial initiations could negatively impact the stock price and cash runway.
Intense Competition: The respiratory biologic market is highly competitive, dominated by established blockbusters such as Dupixent (Sanofi/Regeneron) and Tezspire (Amgen/AstraZeneca).
Future Financing Needs: While funded through 2027, the company will require substantial additional capital to complete Phase 3 development and support commercialization.

Thesis Invalidation Triggers

Failure to secure FDA alignment on Phase 3 trial designs during End-of-Phase 2 meetings in mid-2026.
Unexpected safety signals or lack of efficacy in the ongoing Phase 2 VENTURE trial in COPD or future Phase 3 trials.
Significant delays in initiating Phase 3 trials beyond the projected Q1 2027 timeline.
Rapid depletion of cash reserves leading to premature, highly dilutive equity offerings.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.